Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares Gold Trust (IAU) vs Novavax Inc (NVAX) Price & Performance

iShares Gold TrustTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

iShares Gold Trust vs Novavax Inc — how do they compare? iShares Gold Trust trades at $76.55, while Novavax Inc trades at $8.01 (market cap $1.30B). Which is the better fit depends on your goals.

IAUNVAX
Sector
Commodities - Metals/AgricultureHealth
52-Week High
$101.57$11.19
52-Week Low
$61.62$6.22
Market Cap
$1.30B
Enterprise Value
$800.50M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Gold Trust

IAU, the iShares Gold Trust ETF, trades at $75.35, down 0.2% on the day. Technical indicators are bearish, with moving averages signaling a downtrend and key support at $75. Recent news highlights institutional activity, including a new position by Eurizon Asset Management Hungary Ltd. in Q1 2026, while broader gold sentiment is pressured by expectations of sustained higher interest rates.

The outlook for IAU is influenced by macroeconomic factors affecting gold. Higher-for-longer interest rate expectations from the Fed (WSJ, 2026-07-19) pose a headwind, but structural central bank buying (WSJ, 2026-07-16) offers support. The primary risk is gold's sensitivity to monetary policy, while the opportunity lies in its role as a hedge amid economic uncertainty.

Novavax Inc

Novavax (NVAX) trades at $7.86, down 4.26% on the day amid a bearish technical signal, though it has beaten earnings estimates for the last three quarters. The company reported $1.12 billion in revenue for 2025 with a net income of $440.30 million, yet faces negative shareholder equity and cash flow challenges. Recent news highlights stock volatility and shareholder dissent at the AGM, while analyst consensus remains largely bullish with a $14.00 price target.

The outlook for NVAX hinges on sustaining profitability and managing cash burn, with significant upside potential per analyst targets but substantial risks from negative equity, competitive pressures, and reliance on vaccine demand. Investors must weigh the high volatility and financial health concerns against the optimistic Wall Street ratings.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares Gold Trust

IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.

Read more on IAU

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX